ROS1 tyrosine kinase inhibitors
- Name
- ROS1 tyrosine kinase inhibitors
- Accession Number
- DBCAT005903
- Description
Not Available
- Drugs
Drug Drug Description Repotrectinib A tyrosine kinase inhibitor used to treat locally active or metastatic non-small cell lung cancer Crizotinib A receptor tyrosine kinase inhibitor used to treat metastatic non-small cell lung cancer (NSCLC) where the tumors have been confirmed to be anaplastic lymphoma kinase (ALK), or ROS1-positive. Entrectinib Entrectinib is indicated for the treatment of metastatic ROS1-positive non-small cell lung cancer in adults. Entrectinib is also indicated in adults and children over 12 years old for the treatment... Lorlatinib An anaplastic lymphoma kinase inhibitor used to treat anaplastic lymphoma kinase positive metastatic non small cell lung cancer. Ceritinib An antineoplastic kinase inhibitor used to treat anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) in patients with inadequate clinical response or intolerance to crizotinib. - Drugs & Drug Targets